[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-motility-disorders-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-motility-disorders-in-children":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632917","improvement-of-understanding-of-pediatric-sacral-neuromodulation-therapeutic-strategies-and-outcome-variables-100632917",false,"NCT07519915","Improvement of Understanding of Pediatric Sacral Neuromodulation: Therapeutic Strategies and Outcome Variables","Stimulation Modeling and Adaptive Response Tracking in Pediatric Gastrointestinal Motility Disorders","SMART-GUT","Inclusion Criteria:\n\n* informed consent of patient and care taker\n* gastrointestinal motility disorder, disregarding underlying diseases\n* exclusion of mechanical obstructions in the gastrointestinal passage\n* age between 3 and 18\n\nExclusion Criteria:\n\n* pregnancy\u002Fbreast feeding\n* decreased renal or thyroidal function\n* drug intake of Beta-blockers, antispasmodics, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin\n* contradictions for MRI\n* indication for analgosedation for MRI\n* inflammatory bowel diseases\n* fractures\u002Fdifferent anatomy in sacral region\n* epilepsy\n* presence of cardiac pacemakers","ALL","3 Years","18 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to learn about the effects of sacral neuromodulation in pediatric patients with gastrointestinal motility disorders. By combining advanced neuroimaging, patient-specific biophysical modeling, electrophysiological characterization, and clinical translation, the SMART-GUT project establishes a comprehensive framework to systematically investigate neuromodulation in this pediatric population. This integrative approach enables a direct link between mechanism, targeting, and clinical outcome.",[28,29,30],"Gastrointestinal Motility Disorders in Children","Hirschsprung Disease","Constipation - Functional",[32,33,34,35],"pediatric gastrointestinal motility disorders","chronic constipation","Hirschsprung disease","sacral neuromodulation","RECRUITING","2026-04-06",{"date":39,"type":40},"2026-04-09","ACTUAL",{"date":42,"type":40},"2018-07-01",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"Friedrich-Alexander-Universität Erlangen-Nürnberg","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100506885","bsgm-to-evaluate-patients-with-gi-symptoms-100506885","NCT05880199","BSGM to Evaluate Patients With GI Symptoms","Body Surface Gastric Mapping (BSGM) to Evaluate Patients With Gastrointestinal (GI) Symptoms","Inclusion Criteria for Cases\n\n1. Males or females age 8 to 25 years.\n2. Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.\n3. Confirmed diagnosis of a Functional Gastrointestinal and\u002For Motility Disorder OR undergoing one of the following procedures as part of their clinical care at one of the participating centers:\n\n   1. HRVB\n   2. PENFS\n   3. ADM\n   4. Colonic Manometry\n   5. Pyloric Botox\n   6. Pyloric Dilation\n   7. Gastric Scintigraphy\n   8. GES\n   9. gammaCore\n4. Those with a body mass index of \\\u003C 35.\n5. Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria for Cases\n\n1. History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin. (Please note, majority of feeding tubes can be accommodated by the array placement.)\n2. Pregnant women.\n3. Those with any condition, where fasting is not recommended by a physician.\n4. Any allergies to foods that may be present in the standardized meal that cannot be accommodated with an acceptable substitute meal.\n5. Those with physical limitations, who are not able to maintain a relaxed reclined position for the study visit duration.\n6. Those with major developmental delay or cognitive impairment, who are not able to report their symptoms\u002Ffeelings in the questionnaires.\n7. Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.\n8. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n\nInclusion Criteria for Controls\n\n1. Males or females age 8 to 25 years.\n2. Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.\n3. Do not have an active Functional Gastrointestinal disorder (FGID) diagnosis and will not be undergoing any procedures outlined in the recruitment plan in the near future.\n4. Those with a body mass index of \\\u003C 35.\n5. Individuals may include siblings of those with FGIDs.\n6. Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria for Controls\n\n1. History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin.\n2. Pregnant women.\n3. Those with any condition, where fasting is not recommended by a physician.\n4. Allergies to foods that may be included in the standardized meal that cannot be accommodated with an acceptable substitute meal.\n5. Those with physical limitations, who are not able to maintain a relaxed reclined position for the study duration.\n6. Those with major developmental delay or cognitive impairment, who are not able to report their symptoms\u002Ffeelings in the questionnaires.\n7. Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.\n8. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.",true,"8 Years","25 Years",{"count":60,"type":22},685,"OBSERVATIONAL","The goal of this observational study is to learn about gastric myoelectric activity in children with GI symptoms. The main question it aims to answer is which patterns or signals are associated with GI symptoms as measured by a body surface gastric mapping (BSGM) device. Participants will have their stomach activity recorded for up to 4 hours using the BSGM device and log real-time symptoms. Researchers will compare the recordings of healthy children and children with GI symptoms to define abnormal GI patterns.",[28,64,65,66],"Functional Gastrointestinal Disorders","Gastroparesis","Dyspepsia and Other Specified Disorders of Function of Stomach",[68,69,70],"GI motility","gastroparesis","functional dyspepsia","2026-02-06",{"date":73,"type":40},"2026-02-10",{"date":75,"type":40},"2021-10-01",{"date":77,"type":22},"2028-06-30",{"name":79,"class":47},"Children's Hospital of Philadelphia",5]